Literature DB >> 849987

Inadequate corpus luteal function in women with benign breast diseases.

L R Sitruk-ware, N Sterkers, I Mowszowicz, P Mauvais-Jarvis.   

Abstract

The corpus luteum function of 109 patients with benign breast disease was appreciated by way of plasma progesterone and estradiol determinations during the luteal phase. These patients had ovulatory cycles according to a biphasic basal body temperature curve; blood samples for plasma progesterone and estradiol estimation were collected between the first and the last day of the thermal plateau following the thermal nadir. Results obtained were compared to those observed in 50 normal ovulatory women. In the patients' group, the mean daily levels for progesterone ranged from 3.5 +/- 0.4 (SE) ng/ml to 8.1 +/- 3.8 (SE) ng/ml according to day of blood collection. These values are significantly different from the corresponding daily values observed in normal women. No significant difference was observed concerning plasma estradiol between patients and normal women. These findings indicate that women with benign breast disease have an inadequate corpus luteum function which may be secondary to an ovulation disorder. Pathophysiological implications resulting from this observation are discussed.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 849987     DOI: 10.1210/jcem-44-4-771

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  19 in total

1.  Comparison of fructus agni casti and flurbiprofen in the treatment of cyclic mastalgia in premenopausal women.

Authors:  Tolga Dinç; Faruk Coşkun
Journal:  Ulus Cerrahi Derg       Date:  2014-03-01

Review 2.  The endocrine basis of benign breast disorders.

Authors:  L Dogliotti; F Orlandi; A Angeli
Journal:  World J Surg       Date:  1989 Nov-Dec       Impact factor: 3.352

Review 3.  Epidemiology and endocrinology of benign breast disease.

Authors:  D Y Wang; I S Fentiman
Journal:  Breast Cancer Res Treat       Date:  1985       Impact factor: 4.872

4.  The effect of danazol on the pituitary function, thyroid function, and mastodynia.

Authors:  F Peters; G Reck; G Zimmermann; M Breckwoldt
Journal:  Arch Gynecol       Date:  1980

5.  PRL, TSH, and thyroid hormones in benign breast diseases.

Authors:  F Peters; C R Pickardt; G Zimmermann; M Breckwoldt
Journal:  Klin Wochenschr       Date:  1981-04-15

6.  Corpus luteum dysfunction and the epidemiology of breast cancer: a reconsideration.

Authors:  B M Sherman; R B Wallace; S G Korenman
Journal:  Breast Cancer Res Treat       Date:  1981       Impact factor: 4.872

7.  Luteal phase defect and breast cancer genesis.

Authors:  P Mauvais-Jarvis; R Sitruk-Ware; F Kuttenn
Journal:  Breast Cancer Res Treat       Date:  1982       Impact factor: 4.872

8.  Effects of danazol on incidence of progesterone and oestrogen receptors in benign breast disease.

Authors:  C Panahy; J R Puddefoot; E Anderson; G P Vinson; C L Berry; M J Turner; C L Brown; A W Goode
Journal:  Br Med J (Clin Res Ed)       Date:  1987-08-22

9.  Prostate specific antigen in women with menstrual disturbances and fibrocystic mastopathy.

Authors:  S Radowicki; M Kunicki
Journal:  J Endocrinol Invest       Date:  2009-07-14       Impact factor: 4.256

10.  Chronic hyperprolactinemia and plasma lipids in women.

Authors:  H M Heshmati; G Turpin; J L de Gennes
Journal:  Klin Wochenschr       Date:  1987-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.